Key facts
- GenomeUp’s last known valuation is $6.1M (Feb 2022).
- It has raised $8.1M; the latest was Later Stage VC ($4.9M) in Apr 2025.
- Notable investors include Lazio Innova, CDP Venture Capital (Rome), Zest Group, Angel Partner Group, Finalca — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for GenomeUp
- ·The full record, as it builds
Funding rounds
No funding rounds for GenomeUp are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GenomeUp
Developer of a digital diagnostics platform designed to offer an ecosystem of artificial intelligence-powered technologies for genetic analysis and clinical decision support for diseases. The company's platform offers several bioinformatics tools and protocols to make data and metadata traceable, accessible, interoperable, and reusable, enabling researchers and clinicians to streamline the diagnosis process and offer clinical decision support.
- Sector
- Healthcare
- HQ
- Rome, Italy
- Founded
- 2017
- Employees
- 35
- Website
- genomeup.com/
- Ownership
- Privately Held (backing)
GenomeUp doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenomeUp shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenomeUp in its N-PORT filings yet. We sweep new filings monthly.